UNSPSC 51391725: Mabuterol

This classification denotes a beta-adrenergic agonist with the molecular formula C13H18ClF3N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R4K19W6S7Q, chemically known as benzenemethanol, 4-amino-3-chloro-alpha-(((1,1-dimethylethyl)amino)methyl)-5-(trifluoromethyl)- but generally known as mabuterol, which bears US NIH Compound Identifier 3995. European Medicines Agency schedules Mabuterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08631MIG.

UNSPSC 51391725 Mabuterol is a Commodity code that in recent state and local solicitations maps to procurement of naloxone, drug deactivation systems, and direct-to-manufacturer prescription fulfillment services supporting community health and pharmacy benefit programs. The code shows limited alignment between its nominal scope and the work actually being solicited under it — recent opportunities tag public health emergency-response products and pharmacy-management services that diverge significantly from the code's stated focus. Issuing bodies to date include a county health authority (Seminole County, Florida) and a state health and human services commission (Texas HHS), suggesting the code may be applied inconsistently across jurisdictions or that the code itself has drifted from its original pharmaceutical product definition.

Recent activity centers on Florida and Texas. Seminole County posted an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county health building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026, with same-day response deadline) seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. The mismatch between the code name and the procurement scope — emergency-response pharmaceuticals and pharmacy-benefit program restructuring rather than mabuterol-specific products — suggests the code may see infrequent or misaligned activity in state and local procurement.